Oxibendazole

In response to the economic losses in animal husbandry and the public health prevention and control pressure caused by nematode infections, the clinical value of benzimidazole anthelmintics has long been concerned by the industry. Oxibendazole is a broad-spectrum anthelmintic. It inhibits the tubulin polymerization of parasites, blocks their uptake and utilization of glucose, gradually depletes the glycogen reserve and ATP production of the parasites, and finally makes the parasites unable to survive and reproduce. It is mostly used clinically for the prevention and control of parasitic infections such as gastrointestinal nematodes, lung nematodes, and Fasciola hepatica in livestock and poultry. Meanwhile, it can also be used for the treatment of human trichinosis and echinococcosis, and is a commonly used anthelmintic in the fields of animal husbandry and parasitic disease prevention and control.

At present, the global market size of veterinary anthelmintics exceeds 8 billion US dollars, of which antihelminthic active pharmaceutical ingredients account for about 22%, and the compound annual growth rate remains at 4.7%. With its low toxicity and broad-spectrum properties, the proportion of oxibendazole used in the main production areas of cattle and sheep breeding has been increasing year by year. At present, the domestic production capacity is mainly concentrated in veterinary drug API manufacturers in Jiangsu, Shandong and other regions, and there is no relevant record of centralized volume-based procurement. As this variety was launched early, the market competition is dominated by generic pharmaceutical companies, and the overall price level is relatively stable.

Oxibendazole has no clear single original research enterprise, and belongs to the general anthelmintic developed in the early stage. At present, a number of domestic enterprises have obtained the production approval for its API. Valid A-status registration numbers can be queried on the API registration platform of CDE. The corresponding veterinary preparations and human tablets have all been approved for marketing in China, and the reference preparation is not included in the current *List of Chemical Medicines*. (Data as of November 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for oxibendazole. Most products are available from stock. Stock orders placed before 16:00 can be shipped on the same day. The products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and fully meet the full-process compliance needs of API manufacturers in quality research, qualitative and quantitative analysis of impurities, registration and declaration, etc.